5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer - Wikidata - wikimedia - TriplyDB

5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer

5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer

http://www.wikidata.org/entity/Q34005866

about

Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review Warfarin use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.5-Alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial.Combination of 5α-reductase inhibitor with combined androgen blockade (CAB) as a novel cytoreductive regimen before prostate brachytherapy: Ultra-CAB.Rationale and design of the CANARI study: a case-control study investigating the association between prostate cancer and 5-alpha-reductase inhibitors for symptomatic benign prostate hypertrophy by linking SNIIRAM and pathology laboratories in a spec Obesity and Prostate Cancer.BPH: a tell-tale sign of prostate cancer? Results from the Prostate Cancer and Environment Study (PROtEuS).

P2860

Q28069186-207E3897-6F1D-4F66-ADCA-686DE9593BFE Q40501806-1E9FD928-BA54-45BF-9DE8-E2E4A67FBC1E Q40954634-A68063DC-FF31-464F-8886-3A3882EDC076 Q41192354-387DA18D-305E-4770-B7D2-0F8DB99924ED Q48151197-04215A02-C20B-4F50-8D91-C7C412E2A47B Q50856725-83ED2F3D-DE83-4065-BCC2-E2A7202178CD Q50942062-25292B30-A247-4058-88BA-321FE628AFE5

P2860

5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer

http://www.wikidata.org/entity/Q34005866

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer

@ast

5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer

@en

5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer

@nl

type

label

5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer

@ast

5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer

@en

5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer

@nl

prefLabel

5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer

@ast

5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer

@en

5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer

@nl

P1433

Q34005866-364447D9-DC1E-4363-95F7-36FC82DDF3FF

P1476

Q34005866-795B2C42-9F2E-4C20-9385-EE522EE9603D

P2093

Q34005866-1FF3CBC1-42BD-440E-86DD-553A4C4E0E15

Q34005866-2A7F009D-6C6C-4902-88FC-4F883CEFDF93

Q34005866-320C02F4-6F90-460B-A2A6-128A74E162A5

Q34005866-CAFE4B00-359B-46B4-9228-82E54EAF5F5F

Q34005866-D965E22E-6DC7-4E50-80DB-E5C8A754F1A1

Q34005866-EEC470D1-BCEF-4E34-9F60-F17C16E3AFCD

P2860

Q34005866-055B40A0-9774-4000-8403-52AFB0B8F4F3

Q34005866-14259143-744E-4E96-B86A-23A55046AD85

Q34005866-1953A684-DA14-4A99-824D-6A5F6A1228AA

Q34005866-1EF69BF7-A044-4F46-84B8-99C5964A1ED6

Q34005866-2608592A-A924-40D8-AF98-3E48A6919369

Q34005866-27990043-0A81-412C-88EE-0E2B8D474DF6

Q34005866-28D394B9-091A-4E8F-B10E-E351D5E7326A

Q34005866-2FC07257-FA8D-424A-A182-7E4F58E4CAA3

Q34005866-39D3F99B-139F-4D12-AA2E-8D91BCBD2DFC

Q34005866-3C4FD7C2-0DEA-409F-86EC-F596BB696A2D

P304

Q34005866-9B1B2BE8-FE62-4C00-82D7-BCFC4D698A7B

P31

Q34005866-8DC707CA-FE71-4AFE-B4D4-55B25205E800

P356

Q34005866-020D3AE0-EE4E-456D-AF23-0016B9EA016E

P433

Q34005866-C6C8C1D8-F945-44B8-8875-D0AF2E9381EE

P478

Q34005866-A64CCECD-0F93-40D5-87A1-D8043CBEB048

P50

Q34005866-48D3D7D7-AAF1-4118-A00F-3B32578C5E0C

Q34005866-4F2812D8-7863-4988-8724-7E2751037D99

Q34005866-66F9C9DC-0B48-42BC-B228-D0F8FAD54CA2

Q34005866-A58D03D8-0979-4DA5-BFF3-CA825585E81C

P577

Q34005866-8FA087C5-23B1-48D4-8FF1-7F84E8B1213A

P5875

Q34005866-7502D4DB-9E1B-4704-A713-8FB0FB8DFA4E

P698

Q34005866-D851157A-05D0-4304-AAF9-4936D060B653

P932

Q34005866-A14C6579-5AEC-4F04-9350-F92499EB1371

P356

JAMAINTERNMED.2014.1600

P1433

JAMA Internal Medicine

P1476

5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer

@en

P2093

Aria F Olumi

http://www.w3.org/2001/XMLSchema#string

Christopher Morash

http://www.w3.org/2001/XMLSchema#string

Kathryn M Wilson

http://www.w3.org/2001/XMLSchema#string

Mark A Preston

http://www.w3.org/2001/XMLSchema#string

Rongbin Ge

http://www.w3.org/2001/XMLSchema#string

Sarah C Markt

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of dutasteride on the risk of prostate cancer.

Long-term survival of participants in the prostate cancer prevention trial.

Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia.

Prostate-cancer mortality at 11 years of follow-up.

The influence of finasteride on the development of prostate cancer.

Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.

Coffee consumption and prostate cancer risk and progression in the Health Professionals Follow-up Study.

A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment.

Projecting prostate cancer mortality in the PCPT and REDUCE chemoprevention trials

P304

1301-1307

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMAINTERNMED.2014.1600

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

174

http://www.w3.org/2001/XMLSchema#string

P50

Edward Giovannucci

Lorelei A Mucci

Meir J Stampfer

P577

2014-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262812020

http://www.w3.org/2001/XMLSchema#string

P698

24887392

http://www.w3.org/2001/XMLSchema#string

P932

4122627

http://www.w3.org/2001/XMLSchema#string